Volume 4, Issue 4 (12-2013)
jdc 2013, 4(4): 226-242 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
VandRajabpour F, Raoofian R, Gholamali F, Noormohammadpour P, Hashemzadeh Chaleshtori M, Tabrizi M. Basal cell carcinoma: From molecule to therapy. jdc 2013; 4 (4) :226-242
URL: http://jdc.tums.ac.ir/article-1-5055-en.html
URL: http://jdc.tums.ac.ir/article-1-5055-en.html
Fatemeh VandRajabpour1 
, Reza Raoofian1 , Fatemeh Gholamali2 , Pedram Noormohammadpour2 , Morteza Hashemzadeh Chaleshtori3 , Mina Tabrizi * 4
, Reza Raoofian1 , Fatemeh Gholamali2 , Pedram Noormohammadpour2 , Morteza Hashemzadeh Chaleshtori3 , Mina Tabrizi * 4
1- گروه ژنتیک پزشکی
2- گروه پوست
3- مرکز تحقیقات سلولی و مولکولی
4- گروه ژنتیک پزشکی ,tabrizi@tums.ac.ir
2- گروه پوست
3- مرکز تحقیقات سلولی و مولکولی
4- گروه ژنتیک پزشکی ,
Abstract: (11955 Views)
Basal cell carcinoma (BCC) is the most common cancer in Iran and in the world and its prevalence may become equivalent to the prevalence of all other cancers combined in the future. The Hedgehog (Hh) signaling pathway has an important role in tumorigenesis of BCC. Mutations in PTCH and Smo molecules of this pathway account for 85% to 95% of sporadic BCCs and also most cases of inherited cases. Currently, several treatment methods exist for this cancer. Mohs surgery and removing the whole tumor with free margins are the most efficient way for metastatic and highly invasive BCCs. According to the latest findings, small inhibitor molecules of the Hh pathway are becoming highlighted in drug production. Vismodegib an inhibitor of Smo, was approved by the Food and Drug Administration in 2012 as a drug for metastatic and highly invasive BCCs. Therefore, strategic targeting of signaling molecules has demonstrated success and holds great potential in medicine.
Keywords: basal cell carcinoma, signaling transduction, patched receptor, Smo, Gli1, Mohs surgery, vismodegib
Type of Study: Review |
Subject:
Special
Received: 2013/11/21 | Accepted: 2013/12/22 | Published: 2014/03/9
Received: 2013/11/21 | Accepted: 2013/12/22 | Published: 2014/03/9
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
